The inflammatory bowel disease therapy succeeded in its first major testing, setting up a competition with several large drugmakers.

Insurance data cast doubt on broad recommendations against their use ...

The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” ...

USA: Traditionally, nonsteroidal anti-inflammatory drugs (NSAIDs) are avoided among patients with inflammatory bowel disease ...

Nanoparticles enhance drug solubility, stability, and bioavailability, improving therapeutic outcomes for GI conditions like IBD through targeted delivery mechanisms. Hydrogel-based systems offer ...

A new drug delivery method could improve treatments for inflammatory bowel disease (IBD) like ulcerative colitis and Crohn’s disease. Currently available oral drugs for IBD must transit the entire ...

Scientists headed by a team at the University of British Columbia (UBC) have developed a new approach to drug design that can deliver therapeutics directly to a specific part of the gastrointestinal ...

Ace Therapeutics recently launched in vivo efficacy testing services for IBD drug candidates. Ace Therapeutics, a preclinical contract research provider, announced recently that it has launched in ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the ...

In the UC group, 36.2% of patients who received a low dose of the drug and 47.8% of patients who received a high dose achieved clinical remission compared to 20.45% for placebo. For the CD group, 26.1 ...

Please provide your email address to receive an email when new articles are posted on . Cardiovascular risk-screening and stratification is advised for IBD patients before JAK inhibitor or S1P ...